Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABSW) Cash & Equivalents (2020 - 2025)

SAB Biotherapeutics' Cash & Equivalents history spans 6 years, with the latest figure at $10.5 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 18.03% year-over-year to $10.5 million; the TTM value through Dec 2025 reached $10.5 million, up 18.03%, while the annual FY2025 figure was $10.5 million, 18.03% up from the prior year.
  • Cash & Equivalents reached $10.5 million in Q4 2025 per SABSW's latest filing, down from $29.4 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $56.6 million in Q4 2023 to a low of $2.4 million in Q3 2023.
  • Average Cash & Equivalents over 5 years is $15.8 million, with a median of $11.9 million recorded in 2021.
  • The largest YoY upside for Cash & Equivalents was 279.31% in 2024 against a maximum downside of 84.27% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $33.2 million in 2021, then crashed by 54.69% to $15.0 million in 2022, then skyrocketed by 275.93% to $56.6 million in 2023, then plummeted by 84.27% to $8.9 million in 2024, then rose by 18.03% to $10.5 million in 2025.
  • Per Business Quant, the three most recent readings for SABSW's Cash & Equivalents are $10.5 million (Q4 2025), $29.4 million (Q3 2025), and $3.7 million (Q2 2025).